Compare Ascendis Pharma A/S (ASND) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Nike Inc — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Nike Inc trades at $44.36 (market cap $65.71B). The key difference: Nike Inc is far larger — about 3.7× Ascendis Pharma A/S's market cap, and Nike Inc pays a 3.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NKE | |
|---|---|---|
Market Cap | $17.74B | $65.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $79.24 |
52-Week Low | $163.32 | $40.75 |
Enterprise Value | $18.11B | $67.71B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Nike (NKE) trades at $44.37, up 3.72% in the last session, with a bearish technical signal but recent earnings beats. The company shows strong profitability with a 42.91% gross margin and 22.14% ROE, though revenue declined to $46.31B in 2025. Analysts maintain a $50.80 consensus target with 48.57% buy ratings, while news highlights challenges in China and inventory management.
Nike's outlook is mixed: solid brand strength and margin control support upside, but near-term headwinds in key markets and volatile cash flows pose risks. The stock offers potential for recovery if turnaround strategies gain traction, yet investors face uncertainty from competitive pressures and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
